Hetero Labs Ltd. has identified angiopoietin-1 receptor (TEK; hTIE2), EGFR (HER1; erbB1), hepatocyte growth factor receptor (HGFR; MET), proto-oncogene tyrosine-protein kinase receptor ret (RET; CDHF12; PTC), tyrosine-protein kinase receptor UFO (AXL) and vascular endothelial growth factor receptor 2 (VEGFR2; FLK1) inhibitors reported to be useful for the treatment of cancer.

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has synthesized compounds acting as tyrosine-protein kinase receptor UFO (AXL) inhibitors reported to be useful for the treatment of cancer.

Synthesis and optimization of a series of 1,6-naphthyridin-4-one derivatives led to the identification of the potent AXL inhibitor.

Shanghai Boyue Biotechnology Co. Ltd. has disclosed hepatocyte growth factor receptor (HGFR; MET) and tyrosine-protein kinase receptor UFO (AXL) inhibitors reported to be useful for the treatment of cancer.

Arcus Biosciences Inc. has synthesized tyrosine-protein kinase receptor UFO (AXL) inhibitors reported to be useful for the treatment of viral infection, cancer and fibrosis.

Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has divulged 1,2,4-triazole compounds acting as tyrosine-protein kinase receptor UFO (AXL) inhibitors reported to be useful for the treatment of cancer.

Arcus Biosciences Inc. has disclosed tyrosine...

DUBLIN – Bergenbio ASA raised NOK219.9 million (US$23.9 million) in a private placement priced at NOK18 per share. The fresh injection of cash will enable the Bergen, Norway-based firm to expand its broad development program for lead drug candidate bemcentinib (BGB-324), a first-in-class Axl inhibitor, which is currently in phase II development in acute myeloid leukemia (AML), non-small-cell lung cancer (NSCLC), triple-negative breast cancer and melanoma.